
Antares Pharma, Inc. ATRS
Antares Pharma, Inc. Income Statement 2011-2025 | ATRS
Annual Income Statement Antares Pharma, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
727 M | 768 M | 487 M | 353 M | 341 M | 180 M | 305 M | 604 M | 419 M | 242 M |
Shares |
166 M | 203 M | 163 M | 156 M | 155 M | 147 M | 131 M | 127 M | 110 M | 97 M |
Net Income |
56.2 M | -2.03 M | -6.52 M | -16.7 M | -24.3 M | -20.7 M | -35.2 M | -20.5 M | -11.4 M | -4.39 M |
Revenue |
150 M | 124 M | 63.6 M | 54.5 M | 52.2 M | 45.7 M | 26.5 M | 20.6 M | 22.6 M | 16.5 M |
EBITDA |
16.2 M | 3.55 M | -13.9 M | -14.3 M | -22.3 M | -18.9 M | -33.9 M | -20.3 M | -11.2 M | -4.27 M |
Operating Expenses |
72.9 M | 72.4 M | 49.1 M | 43.5 M | 47.5 M | 46.7 M | 50.4 M | 32.3 M | 24.5 M | 14.1 M |
General and Administrative Expenses |
62.8 M | 61.8 M | 36.8 M | 30.4 M | 26.4 M | 26.9 M | 31.7 M | 8.29 M | 7.2 M | 5.85 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Antares Pharma, Inc. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
BioLife Solutions
BLFS
|
$ 24.56 | 0.7 % | $ 1.13 B | ||
|
Baxter International
BAX
|
$ 19.52 | 1.93 % | $ 9.96 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 200.48 | -0.23 % | $ 57.7 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Ekso Bionics Holdings
EKSO
|
$ 4.68 | 0.21 % | $ 94.4 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Harvard Bioscience
HBIO
|
$ 0.71 | -4.45 % | $ 30.1 M | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
ICU Medical
ICUI
|
$ 148.28 | -0.1 % | $ 3.62 B | ||
|
iRhythm Technologies
IRTC
|
$ 170.21 | 0.82 % | $ 5.31 B | ||
|
Alcon
ALC
|
$ 79.15 | 0.43 % | $ 40.4 B | ||
|
AtriCure
ATRC
|
$ 41.07 | -3.09 % | $ 1.93 B | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
electroCore
ECOR
|
$ 4.85 | 2.11 % | $ 26.7 K | ||
|
Repro Med Systems
KRMD
|
$ 5.8 | 0.35 % | $ 264 M | ||
|
AngioDynamics
ANGO
|
$ 13.42 | 2.13 % | $ 548 M | ||
|
The Cooper Companies
COO
|
$ 81.36 | -0.88 % | $ 16.2 B | ||
|
LeMaitre Vascular
LMAT
|
$ 83.04 | -1.14 % | $ 1.86 B | ||
|
Glaukos Corporation
GKOS
|
$ 111.73 | 2.6 % | $ 5.41 B | ||
|
Masimo Corporation
MASI
|
$ 137.35 | -0.72 % | $ 7.32 B | ||
|
Haemonetics Corporation
HAE
|
$ 80.24 | -3.89 % | $ 4.04 B | ||
|
InfuSystem Holdings
INFU
|
$ 9.22 | -0.27 % | $ 190 M | ||
|
Merit Medical Systems
MMSI
|
$ 86.49 | -0.24 % | $ 5.04 B | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Intuitive Surgical
ISRG
|
$ 559.7 | 3.2 % | $ 199 B | ||
|
OraSure Technologies
OSUR
|
$ 2.49 | - | $ 185 M | ||
|
Microbot Medical
MBOT
|
$ 2.23 | -7.65 % | $ 22.7 M | ||
|
Milestone Scientific
MLSS
|
$ 0.36 | -7.4 % | $ 28.7 M | ||
|
Nephros
NEPH
|
$ 4.98 | -0.8 % | $ 51.7 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
ResMed
RMD
|
$ 251.67 | -0.27 % | $ 36.8 B | ||
|
Envista Holdings Corporation
NVST
|
$ 22.07 | 0.46 % | $ 3.8 B | ||
|
Pro-Dex
PDEX
|
$ 44.0 | 1.43 % | $ 145 M | ||
|
STAAR Surgical Company
STAA
|
$ 23.49 | -2.65 % | $ 1.15 B | ||
|
STERIS plc
STE
|
$ 253.98 | 0.82 % | $ 25 B | ||
|
Stereotaxis
STXS
|
$ 2.35 | -1.05 % | $ 190 M | ||
|
Pulse Biosciences
PLSE
|
$ 14.04 | -1.4 % | $ 674 M | ||
|
Predictive Oncology
POAI
|
- | - | $ 32.4 M | ||
|
Repligen Corporation
RGEN
|
$ 160.09 | 1.72 % | $ 8.92 M | ||
|
Utah Medical Products
UTMD
|
$ 57.54 | -0.96 % | $ 209 M | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.43 | -1.21 % | $ 2.32 B | ||
|
Retractable Technologies
RVP
|
$ 0.84 | 1.99 % | $ 25.1 M | ||
|
Teleflex Incorporated
TFX
|
$ 126.88 | 0.17 % | $ 5.94 B | ||
|
West Pharmaceutical Services
WST
|
$ 271.82 | 1.6 % | $ 19.8 B |